Galmed Pharmaceuticals (NASDAQ:GLMD) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Galmed Pharmaceuticals in a report on Friday, April 4th.

Galmed Pharmaceuticals Stock Performance

Shares of GLMD stock opened at $1.19 on Thursday. The firm’s 50-day moving average is $1.53 and its 200-day moving average is $2.36. The stock has a market cap of $1.97 million, a price-to-earnings ratio of -0.07 and a beta of 0.49. Galmed Pharmaceuticals has a 52-week low of $1.15 and a 52-week high of $23.80.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC purchased a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned 3.97% of Galmed Pharmaceuticals as of its most recent SEC filing. 76.14% of the stock is currently owned by institutional investors and hedge funds.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.